68-5
54/120

1) Hyuna S, Jacques F, Rebecca L, et al: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Coun-tries. CA Cancer J Clin, 2021; 71: 209-249. 2) Lin Y, Totsuka Y, He Y, et al: Epidemiology of esopha-geal cancer in Japan and China. J Epidemiol, 2013; 23: 233-242. 3) Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, ESMO Guidelines Working Group: Oesopha-geal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013; Suppl 6: vi 51-56. 4) Zhang HZ, Jin GF, Shen HB: Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer, 2012; 31: 281-286. 5) Bijland LR, Bomers MK, Smulders YM: Smelling the diagnosis: a review on the use of scent in diagnosing disease. Neth J Med, 2013; 71: 300-307. 6) Amann A, Spaněl P, Smith D: Breath analysis: the approach towards clinical applications. Mini Rev Med Chem, 2007; 7: 115-129. 7) Mazzone PJ: Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer. J Thorac Oncol, 2008; 3: 774-780. 8) McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T: Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integr Cancer Ther, 2006; 5: 30-39. 9) Preti G, Labows JN, Kostelc JG, Aldinger S, Daniele R: Analysis of lung air from patients with bronchogenic carcinoma and controls using gas chromatography- mass spectrometry. J Chromatogr, 1988; 432: 1-11. 10) Phillips M: Breath tests in medicine. Sci Am, 1992; 267: 74-79.11) Phillips M, Cataneo RN, Ditkoff BA, et al: Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res Treat, 2006; 99: 19-21.12) Kumar S, Huang J, Abbassi-Ghadi N, Španěl P, Smith D, Hanna GB: Selected ion flow tube mass spectrom-504No funding was received.Author contributionsSM and YK made a study design, recruited patients and volunteers as control, collected data, analyzed, and interpreted the patient data and SM was a major contributor in writing the manuscript. NK, HT, TF, and TU performed the examination of the gas chromatography-mass spectrometry (GC- MS). TH and MN revised the article, and all authors approved the final manuscript.Conflicts of interest statementThe Authors declare that there are no conflicts of interest.Referencesetry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer. Anal Chem, 2013; 85: 6121-6128.13) Kumar S, Huang J, Abbassi-Ghadi N, et al: Mass spec-trometric analysis of exhaled breath for the identifica-tion of volatile organic compound Biomarkers in esoph-ageal and gastric adenocarcinoma. Ann Surg, 2015; 262: 981-990.14) Pierce KM, Hoggard JC, Hope JL, et al: Fisher ratio method applied to third-order separation data to indentify significant chemical components of metabolic extracts. Anal Chem, 2006; 78: 5068-5075. 15) Spratlin JL, Serkova NJ, Eckhardt SG: Clinical applica-tions of metabolomics in oncology: a review. Clin Cancer Res, 2009; 15: 431-440.16) Thysell E, Surowiec I, Hörnberg E, et al: Metabolomic characterization of human prostate cancer bone metas-tases reveals increased levels of cholesterol. PLoS One, 2010; 5: e14175.17) Wu H, Xue R, Lu C, et al: Metabolomic study for diag-nostic model of oesophageal cancer using gas chroma-tography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2009; 877: 3111-3117.18) Kneepkens CM, Lepage G, Roy CC: The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic Biol Med, 1994; 17: 127-160.19) Bajaj A, Miranda OR, Kim IB, et al: Detection and differentiation of normal, cancerous, and metastatic cells using nanoparticle-polymer sensor arrays. Proc Natl Acad Sci USA, 2009; 106: 10912-10916. 20) Barash O, Peled N, Hirsch FR, Haick H: Sniffing the unique ‘odor print’ of non-small-cell lung cancer with gold nanoparticles. Small, 2009; 5: 2618-2624.21) Filipiak W, Sponring A, Filipiak A, et al: TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in-vitro. Cancer Epidemiol Biomarkers Prev, 2010; 19: 182-195.22) Horváth I, Lázár Z, Gyulai N, Kollai M, Losonczy G: Exhaled biomarkers in lung cancer. Eur Respir J, 2009; 34: 261-275.23) Altomare DF, Lena MD, Porcelli F, et al: Exhaled vola-tile organic compounds identify patients with colorectal cancer. Br J Surg, 2013; 100: 144-150.24) Huang J, Kumar S, Abbassi-Ghadi N, Spaněl P, Smith D, Hanna GB: Selected ion flow tube mass spectrom-etry analysis of volatile metabolites in urine headspace for the profiling of gastro-esophageal cancer. Anal Chem, 2013; 85: 3409-3416.25) Yu Z, Lei G, Zhongzhi Q, Yang L, Guangmin C, Enyou Li: Early diagnosis of breast cancer from exhaled breath by gas chromatography-mass spectrometry (GC/MS) analysis: A prospective cohort study. J Clin Lab Anal, 2020; 34: e23526.26) Haitham A, Marcis L, Konrads F, et al: Breath testing as potential colorectal cancer screening tool. Int J Cancer, 2016; 138: 229-236.27) Chen X, Muhammad K, Madeeha C, et al: Calculated indices of volatile organic compounds (VOCs) in exha-lation for lung cancer screening and early detection. Lung Cancer, 2021; 154: 197-205.28) Leja MA, Liu H, Haick H: Breath testing: the future for digestive cancer detection. Expert Rev Gastroenterol Hepatol, 2013; 7: 389-391.Funding

元のページ  ../index.html#54

このブックを見る